Sort
15,440 grants matching “organoids”
Trophoblast progenitor heterogeneity and function in normal and Trisomy 21-affected placentae
$644,698Mana M Parast · University Of California, San Diego · R01 · FY2025 · HD
Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
$644,585Murat Gunel · Yale University · R01 · FY2024 · NS
The miR-20/c-Myc/E2F Regulatory Axis is Critical for the Tumor Promoting Activity of Inflammatory Fibroblasts in Colitis-Associated Cancer
$644,486Emina Hui-Na Huang · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · CA
Prenatal Origins of Neurometabolic Consequences
$644,433Sherin U. Devaskar · University Of California Los Angeles · R01 · FY2022 · HD
Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer
$644,430Xiling Shen · Duke University · U01 · FY2020 · CA
Validation of a novel 3D culture platform for TNBC treatment selection
$644,226Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2022 · CA
Enteric virus exploitation of calcium signaling
$644,109Joseph M. Hyser · Baylor College Of Medicine · R01 · FY2023 · DK
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies
$644,078Anirban Maitra · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Prenatal Origins of Neurometabolic Consequences
$643,987Sherin U. Devaskar · University Of California Los Angeles · R01 · FY2021 · HD
Development of functionalized SARM1 nanobodies for glaucoma
$643,952Derek Stuart Welsbie · University Of California, San Diego · R01 · FY2025 · EY
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers
$643,951Brian B Haab · Van Andel Research Institute · U01 · FY2022 · CA
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
$643,856Calvin J Kuo · Stanford University · R01 · FY2023 · CA
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer
$643,764Nupam P Mahajan · Washington University · R01 · FY2025 · CA
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
$643,552Calvin J Kuo · Stanford University · R01 · FY2022 · CA
Bioengineering adipocytes for cancer therapy
$643,369Nadav Ahituv · University Of California, San Francisco · R01 · FY2025 · CA
Drug Development of Skp2 PROTACs in Cancer
$643,253Hong-Yu Li · University Of Texas Hlth Science Center · R01 · FY2025 · CA
Bioengineering adipocytes for cancer therapy
$643,221Nadav Ahituv · University Of California, San Francisco · R01 · FY2024 · CA
Design and characterization of bacterial population dynamics in solid tumor models
$642,937Jeff M Hasty · University Of California, San Diego · R01 · FY2021 · EB
Integrating Epigenetic Modulation into DNA Damage Repair
$642,872Pamela N Munster · University Of California, San Francisco · R01 · FY2023 · CA
SARS-CoV-2 tropism in the brain and its relationship to COVID-19 pathogenesis
$642,597Abraam M. Yakoub · University Of North Dakota · R01 · FY2021 · HL
Investigating protective adaptive immune responses to influenza antigens using human tonsil organoids
$642,584Lisa Wagar · University Of California-Irvine · R01 · FY2023 · AI
3D molecular phenotyping of intact brain tissue via high-throughput active immunohistochemistry
$642,500Adam C Hall · Lifecanvas Technologies, Inc. · R44 · FY2021 · MH
A premalignant chronology of cell-state variability in basal-like breast cancer
$642,376Kevin A Janes · University Of Virginia · R01 · FY2023 · CA
PPARD hyperactivation promotes pancreatic intraepithelial neoplasia progression into pancreatic ductal adenocarcinoma
$642,368Imad Shureiqi · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)
$642,310William Robert Jarnagin · Sloan-Kettering Inst Can Research · U01 · FY2023 · CA